Phase Ib, Single-Centre, Placebo-Controlled Randomised Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Elsulfavirine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Viriom
- 22 May 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 16 May 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 16 May 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Nov 2019.